Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This is a multicohort phase 2 study to evaluate the efficacy of pembrolizumab combined with
the investigational drug sitravatinib in the frontline treatment of advanced, non-squamous
PD-L1 positive NSCLC.